Press Releases

September 1, 2015

Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board

August 6, 2015

Nevro Reports Second Quarter 2015 Financial Results

July 28, 2015

Nevro Announces Publication of SENZA-RCT Results in Anesthesiology

July 23, 2015

Nevro to Report Operating Results for the Second Quarter 2015

June 29, 2015

Nevro Appoints Lisa Earnhardt to its Board of Directors

June 23, 2015

Nevro Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

June 10, 2015

Nevro to Present at the JMP Securities Life Sciences Conference

June 3, 2015

Nevro Announces Pricing of Upsized Public Offering of Common Stock

June 1, 2015

Nevro Announces Proposed Public Offering of Common Stock

May 22, 2015

Nevro Announces First Commercial Procedure of HF10™ Therapy in the United States

May 18, 2015

Nevro Files S-1 Registration Statement for Proposed Primary and Secondary Public Offering

May 11, 2015

Nevro Announces Filing of Petitions for Inter Partes Review of U.S. Patent No. 8,359,102

May 11, 2015

Nevro Reports First Quarter 2015 Financial Results

May 8, 2015

Nevro Receives FDA Approval for Senza® Spinal Cord Stimulation System Delivering HF10™ Therapy

April 28, 2015

Nevro to Report Operating Results for the First Quarter 2015

March 18, 2015

Nevro Reports Fourth Quarter and Full Year 2014 Financial Results

March 4, 2015

Nevro to Report Operating Results for the Fourth Quarter and Full Year of 2014

March 2, 2015

Nevro Appoints Dr. Brad Vale to its Board of Directors

February 4, 2015

Nevro Receives Expanded MR-Conditional Labeling for Senza® Spinal Cord Stimulation System in Europe and Australia

January 28, 2015

Nevro to Present at the 2015 Leerink Global Healthcare Conference

January 22, 2015

Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza® Spinal Cord Stimulation System

December 29, 2014

Nevro to Present at the J.P. Morgan 33rd Annual Healthcare Conference

December 15, 2014

Nevro Announces First Draw Down of $20 Million Under Term Loan Facility with CRG

December 2, 2014

Nevro Reports Third Quarter Financial Results

November 13, 2014

Nevro to Report 2014 Third Quarter Financial Results and Host Conference Call on December 2, 2014

November 12, 2014

Nevro Corp. Announces Full Exercise of Over-Allotment Option and Closing of Initial Public Offering

November 6, 2014

Nevro Corp. Announces Pricing of Initial Public Offering

August 25, 2014

Nevro Announces Issuance of Key European & Australian Patents for Innovative Chronic Pain Treatment

March 31, 2014

Nevro Strengthens Leadership Team with the Appointment of David Caraway, MD, PhD as Chief Medical Officer

March 12, 2014

Nevro Corp. Completes Enrollment of U.S. Randomized Pivotal Trial of Novel Chronic Pain Treatment

March 11, 2014

Nevro Corp. Announces Publication of 24-month European Clinical Data on HF10 Spinal Cord Stimulation (SCS) Therapy for Chronic Back and Leg Pain

March 7, 2013

Nevro Corp. Closes $48 Million in New Financing

February 6, 2013

Nevro Corp. Announces Publication of Positive Six-Month Clinical Data for Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy in Europe

January 24, 2013

Nevro Announces Issuance of Additional Key U.S. Patents for Innovative Chronic Pain Treatment

October 2, 2012

FierceMedicalDevices Names Nevro Corp. as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012

July 10, 2012

First Patient Treated in Landmark U.S. Randomized Pivotal Trial of Nevro’s Chronic Pain Treatment

June 27, 2012

Nevro Announces Issuance of Key U.S. Patents for Innovative Chronic Pain Treatment

May 23, 2012

Nevro Receives FDA Approval to Initiate Landmark U.S. Randomized Pivotal Trial of Innovative Chronic Pain Treatment

July 19, 2011

Nevro Corp Closes $58 Million in New Financing

March 16, 2011

Nevro Appoints Michael DeMane President and Chief Executive Officer

PATIENT EXPERIENCES

SENZA

Almost 9 of 10 patients preferred Nevro's HF10 therapy over traditional SCS.

Find Out Why »